

Substitute for form 1448A/PTO (Modified)			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/617,927	
			Filing Date	July 10, 2003	
			First Named Inventor	BROWN, Dennis M.	
			Art Unit	1614 <i>VLSI</i>	
			Examiner Name	To Be Assigned <i>LILLIARD</i>	
Sheet	1	of	2	Attorney Docket Number	A-71604/RFT/THR (468899-00035)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
<i>VLS</i>	A0	4,675,318	06-23-1987	Liu	
	A1	4,783,454	11-08-1988	Liu	
	A2	6,630,173 B2	05-11-2004	Brown	
<i>VLS</i>	A3	6,734,178 B2	05-11-2004	Brown	


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
	B1	WO 01/68098 A2/A3	09-20-2001	ChemGenex Therapeutics, Inc.		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ⁴
VLS	C1	ABBOTT, B.J., et al., "Screening Data from the Cancer Chemotherapy National Service Center Screening Laboratories. XXXVI. Plant Extracts," <i>Cancer Res. Supp.</i> , 26(9):1131-1136 (Sep. 1966).				
	C2	AJANI, J., et al., "Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas," <i>Cancer Treat. Rep.</i> 70(3):375-379 (Mar. 1986).				
	C3	FELDMAN, E., et al., "Homoharringtonine is safe and effective for patients with acute myelogenous leukemia," <i>Leukemia</i> 6(11):1185-1188 (Nov. 1992).				
	C4	GÜNTHER, A., et al., "Differential expression of intermediate-filament proteins in murine sarcoma 180 ascites or solid tumor," <i>Cancer Res.</i> 44(6):2590-2594 (Jun. 1984).				
	C5	JIN, X., et al., "Cisplatin combination therapy of murine S180," <i>Shanghai Yike Daxue Xuebao</i> , 16(1):50-54 (1989), Caplus Accession No. 1989:225174, (Abstract only).				
	C6	KANTARJIAN, H.M., et al., "Homoharringtonine: History, Current Research, and Future Directions," <i>Cancer</i> 92(6):1591-1605 (Sep. 2001).				
	C7	LASTER, W.R., et al., "Therapeutic synergism (TS) of homoharringtonine (H) plus 5-fluorouracil (FU) against leukemia P388 (P388/O) and ARA-C-resistant P388 (P388/ARA-C)," <i>Proc. Am. Assn. Cancer Res.</i> , 23:786 (1982), Embase Accession No. 82182588, (Abstract only).				
	C8	MAGNUSSON, K., et al., "Is conversion of solid into more anoxic ascites tumors associated with p53 inactivation?," <i>Oncogene</i> 17(5):2333-2337 (Nov. 1998).				
	C9	POWELL, R.G., "Antitumor alkaloids for <i>Cephalotaxus harringtonia</i> : structure and activity," <i>J. Pharm. Sci.</i> 61(8):1227-1230 (Aug. 1972).				
	C10	PROVENCHER, D., et al., "Discordance in p53 mutations when comparing ascites and solid tumors from patients with serous ovarian cancer," <i>Tumor Biol.</i> 18(3):167-174 (1997).				
	C11	RUNGE-MORRIS, M.A., et al., "Evaluation of Homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: A phase II Illinois Cancer Council Study," <i>Invest. New Drugs</i> 7(2-3):269-273 (Jul. 1989).				
VS	C12	SAVAGE, K.E., et al., "Effect of tunicamycin, an inhibitor of protein glycosylation, on division of tumour cells <i>in vitro</i> ," <i>J. Cell Sci.</i> 64:295-306 (Nov. 1983).				

Examiner Signature	<i>Hester J. Lee</i>	Date Considered	01/30/06
--------------------	----------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2



Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/617,927
				Filing Date	July 10, 2003
				First Named Inventor	BROWN, Dennis M.
				Art Unit	1614 <i>1651</i>
				Examiner Name	To Be Assigned <i>Enoch</i>
Sheet	2	of	2	Attorney Docket Number	A-71604/RFT/THR (468899-00035)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	†
<i>MB</i>	C13	TAKANO, I., et al., "Ester-type cephalotaxus alkaloids from <i>Cephalotaxus harringtonia</i> var. <i>drupacea</i> ," <i>Phytochemistry</i> , 44(4):735-738 (1997).	
	C14	TAKANO, I., et al., "New oxygenated cephalotaxus alkaloids from <i>Cephalotaxus harringtonia</i> var. <i>drupacea</i> ," <i>J. Nat. Prod.</i> 59(12):1192-1195 (Dec. 1996).	
	C15	VISANI, G., et al., "Effects of homoharringtonine alone and in combination with α interferon and cytosine arabinoside on <i>in vitro</i> growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors," <i>Leukemia</i> 11:624-628 (May 1997).	
	C16	WARRELL, R.P., et al., "Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia," <i>J. Clin. Oncol.</i> 3(5):617-621 (May 1985).	
	C17	WITTE, R.S., et al., "A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer," <i>Invest. New Drugs</i> 14(4):409-413 (1996).	
	C18	WITTE, R.S., et al., "A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer," <i>Invest. New Drugs</i> 17(3):173-177 (1999).	
	C19	YUZHU, Z., et al., "Homoharringtonine, cytarabine and aclarubicin (HAA) combination chemotherapy for acute myeloid leukemia (AML)," <i>Chin. J. Clin. Oncol.</i> , 25(10):758-759 (1998), Embase Accession No. 1998384948, (Abstract only).	
	C20	ZHANG, S.D., et al., "Inhibitory effects of homoharringtonine and hydroxycamptothecin in combination with other agents on cancer cell growth," <i>Asia Pac. J. Pharmacol.</i> , 7:191-195 (1992).	
<i>Y</i>	C21	ZHOU, D.C., et al., "Homoharringtonine: an effective new natural product in cancer chemotherapy," <i>Bull. Cancer</i> 82(12):987-995 (Dec. 1995).	

Examiner Signature	<i>John J. Heller</i>	Date Considered	01/30/06
--------------------	-----------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English Language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2